Skip to main content
main-content

Oncology

Latest articles

19-02-2020 | Oncology | News | Article

EV-103 update bolsters enfortumab vedotin–pembrolizumab potential in urothelial carcinoma

Durability and survival results from the phase 1b EV-103 trial provide further support for the combination of enfortumab vedotin and pembrolizumab as a promising first-line option for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

19-02-2020 | Oncology | News | Article

COSMIC-021: Cabozantinib–atezolizumab duo promising for mCRPC

The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.

18-02-2020 | Oncology | News | Article

ATLAS: Disappointing results for rucaparib in urothelial carcinoma

Results of the phase 2 ATLAS trial do not support use of the PARP inhibitor rucaparib in patients with recurrent, locally advanced, or metastatic urothelial carcinoma, the investigators have reported.

18-02-2020 | Oncology | News | Article

Further investigation of combined immunotherapy, SBRT may be warranted for mRCC

Findings from two phase 2 trials suggest that combining immune checkpoint inhibition with stereotactic body radiotherapy is feasible in patients with metastatic renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

16-02-2020 | Oncology | News | Article

Chemotherapy de-escalation feasible in metastatic seminoma

SEMITEP trial results reported at the 2020 Genitourinary Cancers Symposium demonstrate the feasibility of treatment de-escalation based on an interim scan in metastatic seminoma patients with good prognosis.

15-02-2020 | Oncology | News | Article

Novel gene therapy shows promise in non-muscle-invasive bladder cancer

The adenovirus vector-based gene therapy nadofaragene firadenovec elicits durable responses in people with non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin, shows a phase 3 trial.

Image Credits